The identification of a specific immunogenic candidate that will effectively activate the appropriate pathway for neutralizing antibody production is fundamental for vaccine design. By using a monoclonal antibody (1H8) that neutralizes HCV in vitro, we have demonstrated here that 1H8 recognized an epitope mapped between residues A524 and W529 of the E2 protein. We also found that the epitope residues A524, P525, Y527 and W529 were crucial for antibody binding, while the residues T526, Y527 and W529 within the same epitope engaged in the interaction with the host entry factor CD81. Furthermore, we detected “1H8-like” antibodies, defined as those with amino acid-specificity similar to 1H8, in the plasma of patients with chronic HCV infection. The time course study of plasma samples from Patient H, a well-characterized case of post-transfusion hepatitis C, showed that “1H8-like” antibodies could be detected in a sample collected almost two years after the initial infection, thus confirming the immunogenicity of this epitope in vivo. The characterization of this neutralization epitope with a function in host entry factor CD81 interaction should enhance our understanding of antibody-mediated neutralization of HCV infections.
References
[1]
Centers for Disease Control and Prevention (2012) CDC Health Information for International Travel (Oxford Univ Press, New York).
[2]
Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345: 41–52.
[3]
Alter HJ, Liang TJ (2012) Hepatitis C: The end of the beginning and possibly the beginning of the end. Ann Intern Med 156: 317–318.
[4]
Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF (2009) Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 8: 333–345.
[5]
Halliday J, Klenerman P, Barnes E (2011) Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines 10: 659–672.
[6]
Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, et al. (1999) Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 73: 6235–6244.
[7]
Heile J, Fong Y, Rosa D, Berger K, Saletti G, et al. (2000) Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. J Virol 74: 6885–6892.
[8]
Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, et al. (1998) Binding of hepatitis C virus to CD81. Science 282: 938–941.
[9]
Logvinoff C, Major M, Oldach D, Heyward S, Talal A, et al. (2004) Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 101: 10149–10154.
[10]
Yu MY, Bartosch B, Zhang P, Guo ZP, Renzi PM, et al. (2004) Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A 101: 7705–7710.
[11]
Yei S, Yu M, Tankersley D (1992) Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion 32: 824–828.
[12]
Zhang P, Wu C, Mihalik K, Virata-Theimer ML, Yu MY, et al. (2007) Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci U S A 104: 8449–8454.
[13]
Zhang P, Yu M, Venable R, Alter H, Shih J (2006) Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees. Proc Natl Acad Sci U S A 103: 9214–9219.
[14]
Zhong L, Haynes L, Struble EB, Tamin A, Virata-Theimer ML, et al. (2009) Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein. Biochem Biophys Res Commun 390: 1056–1060.
[15]
Mateu G, Donis RO, Wakita T, Bukh J, Grakoui A (2008) Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death. Virology 376: 397–407.
[16]
Pestka JM, Zeisel MB, Bl？ser E, Schürmann P, Bartosch B, et al. (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. . Proc Natl Acad Sci U S A 104: 6025–6030.
[17]
von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, et al. (2007) Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132: 667–678.
[18]
Fafi-Kremer S, Fofana I, Soulier E, Carolla P, Meuleman P, et al. (2010) Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 207: 2019–2031.
[19]
Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85: 3173–3188.
[20]
Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, et al. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962–973.
[21]
Bukh J, Miller RH, Purcell RH (1995) Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15: 41–63.
[22]
Martell M, Esteban JI, Quer J, Genescà J, Weiner A, et al. (1992) Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 66: 3225–3229.
[23]
Clayton RF, Owsianka A, Aitken J, Graham S, Bhella D, et al. (2002) Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol 76: 7672–7682.
[24]
Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH (2001) Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 82: 1877–1883.
[25]
Roccasecca R, Ansuini H, Vitelli A, Meola A, Scarselli E, et al. (2003) Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J Virol 77: 1856–1867.
[26]
Yagnik AT, Lahm A, Meola A, Roccasecca RM, Ercole BB, et al. (2000) A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40: 355–366.
[27]
Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, et al. (2006) Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol 80: 8695–8704.
[28]
Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, et al. (2007) Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A 104: 16269–16274.
[29]
Keck ZY, Li TK, Xia J, Gal-Tanamy M, Olson O, et al. (2008) Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol 82: 6061–6066.
[30]
Law M, Maruyama T, Lewis J, Giang E, Tarr AW, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14: 25–27.
[31]
Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJ, et al. (2006) Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43: 592–601.
[32]
Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, et al. (2006) High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 281: 18285–18295.
[33]
Keck ZY, Xia J, Wang Y, Wang W, Krey T, et al. (2012) Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog 8: e1002653 doi: 10.1371.
[34]
Drummer H, Boo I, Maerz A, Poumbourios P (2006) A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J Virol 80: 7844–7853.
[35]
Meyer K, Basu A, Przysiecki CT, Lagging LM, Di Bisceglie AM, et al. (2002) Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol 76: 2150–2158.
